%20(1).webp)
In recent months, a specific narrative has emerged in UK media coverage: that private ADHD and autism clinics are exploiting vulnerable patients by offering buy-now-pay-later payment options such as Klarna for assessments costing hundreds of pounds.
The framing is superficially compelling. It touches on concerns about patient vulnerability, financial risk, and the ethics of private healthcare. But it contains a critical flaw: it interprets the financial behaviour of people with ADHD through a neurotypical lens, without accounting for the well-established neurological and economic reality of the condition it is discussing.
This article sets out the evidence. It explains what the research actually shows about ADHD and financial functioning, why payment plans are not an exploitation mechanism but an accessibility adjustment, and why any commentary on this topic that ignores the state of NHS ADHD services is, at best, incomplete.
A Times article titled "Patients offered buy now, pay later deals on autism and ADHD tests" framed the availability of Klarna and similar payment options at private ADHD clinics as inherently problematic, implying either financial irresponsibility on the part of patients or exploitation by providers.
This framing has been echoed in related commentary that questions whether ADHD assessments represent appropriate uses of credit-style payment structures, and whether people with ADHD should be accessing these products at all.
There is a legitimate public interest in scrutinising private healthcare markets and ensuring that vulnerable individuals are not exploited. That scrutiny is appropriate and necessary. But it must be grounded in clinical accuracy. And this particular body of coverage, so far, has not been.
ADHD is a neurodevelopmental condition with measurable, well-documented effects on financial functioning. This is not a contested clinical area. Decades of large-scale longitudinal research have consistently demonstrated that adults with ADHD experience elevated rates of financial difficulty compared to the general population, and that this difficulty is neurological in origin rather than a reflection of character, intelligence, or moral failing.
Barkley and colleagues, in studies published in 2006 and 2008, documented significantly poorer financial management, higher rates of credit problems, and reduced occupational attainment in adults with ADHD compared to neurotypical controls. These findings have been replicated across multiple research groups and populations.
Fletcher's 2014 research found that childhood ADHD is associated with lower adult earnings and reduced employment stability, independent of intelligence and educational attainment. The mechanism is not cognitive capacity. It is the executive function difficulties that ADHD creates in managing the day-to-day demands of employment.
Kessler and colleagues estimated a substantial annual economic burden attributable to untreated adult ADHD in the USA alone, driven by functional impairment across educational, occupational, and social domains.
The picture that emerges from this research is consistent and clear: adults with ADHD are more likely to struggle financially, not because they make worse decisions in any fundamental sense, but because the neurological differences that define ADHD directly impair the executive function skills that financial management requires. For more on how ADHD's executive function difficulties affect everyday life, see our article on the role of executive function in ADHD.
The term ADHD tax is not a social media trend. It describes the cumulative financial burden that falls on people with ADHD as a direct consequence of their neurological differences. It includes late payment fees incurred because of poor time management, money spent replacing lost items, financial penalties from missed deadlines, inefficiencies in purchasing decisions driven by impulsivity, and the income reduction associated with underemployment and career instability.
Research supports all of these dimensions. The ADHD tax is real, measurable, and experienced across the lifespan by a significant proportion of adults with ADHD. It is not evidence of irresponsibility. It is evidence of what happens when a neurological condition that affects financial decision-making goes unidentified and unsupported.
This context is essential for any responsible discussion of how people with ADHD navigate the cost of private assessment. The people seeking these assessments are often not making an impulsive financial decision. Many have already been paying the ADHD tax, emotionally, financially, and professionally, for years or decades. An assessment is not the beginning of their financial exposure to ADHD. It is a step towards addressing it.
ADHD is associated with specific neuropsychological impairments that directly affect how financial decisions are made and managed. Two are particularly relevant to this discussion.
Time blindness is the difficulty accurately perceiving and using the passage of time, a feature of ADHD that Toplak and colleagues documented in 2006 in research showing impaired time estimation and temporal foresight in individuals with ADHD. For someone with significant time blindness, a single large upfront payment can feel cognitively equivalent to a more distant abstraction, while a structured series of regular smaller payments maps more naturally onto the closer temporal horizon that the ADHD brain processes most effectively.
Delayed-reward discounting is the neurological tendency, well-documented in ADHD research by Sonuga-Barke, Castellanos and others, for the ADHD brain to weight immediate costs and benefits more heavily than future ones. This is not a character flaw. It is a feature of how dopamine systems function differently in ADHD. It means that a large immediate payment creates a much higher cognitive and emotional barrier to action than the same total amount distributed over time.
For many people with ADHD, a manageable monthly payment for something immediately beneficial is genuinely more financially tractable than a single large upfront payment, not because they cannot afford it in aggregate, but because of how their brain processes temporal distance and immediate cost. This is adaptive financial structuring, not recklessness.
For more on ADHD's effects on impulse control and financial decision-making, see our article on ADHD impulse control in adults.
The clinical and neuropsychological evidence supports a straightforward conclusion: for a significant proportion of adults with ADHD, structured instalment payment plans reduce cognitive overload at the point of decision-making, improve predictability in budgeting, and support follow-through with assessment and treatment rather than avoidance of it.
These are not incidental benefits. They directly address the specific neurological barriers that ADHD creates around healthcare-seeking behaviour. Adults with ADHD are already at elevated risk of healthcare avoidance driven by the executive function difficulties, emotional dysregulation, and overwhelm associated with navigating complex systems. A financial structure that reduces the activation energy required to access care is therefore clinically meaningful.
Framing this as exploitation requires ignoring both the neurodevelopmental research and the straightforward logic of how payment structures interact with ADHD neurocognition.
In healthcare ethics and disability-inclusive practice, accessibility is not limited to physical access. Financial accessibility is a recognised and important dimension of ensuring that care reaches the people who need it.
Structured payment plans, including those delivered through services like Klarna, can be understood as financial accessibility adjustments in the same conceptual framework that underpins reasonable adjustments under disability law. They reduce a barrier to access that is disproportionately experienced by the neurodivergent population seeking care.
The relevant question is not whether payment plans carry theoretical financial risks, which all payment instruments do, but whether they are offered transparently, ethically, and in a way that supports rather than exploits the individuals using them. Ethical providers offering transparent payment options with clear terms are doing something clinically reasonable, not something exploitative.
The contrast worth drawing is not between Klarna and no Klarna. It is between accessible private care and no care. For the many adults who cannot access timely NHS assessment, the choice is not between two routes to the same destination. It is between assessment and continued years of unidentified, unsupported ADHD.
Any commentary on private ADHD assessment and payment plans that does not engage with the current state of NHS ADHD services is missing the most important part of the picture.
Across the UK, adults seeking ADHD assessment through NHS pathways face waiting times that are measured not in months but in years. In some regions, NHS waiting lists for adult ADHD assessment now extend to five to ten years. Proposals to restrict the Right to Choose pathway, which has enabled patients to access approved providers more quickly, threaten to make this situation worse. For more on the current state of NHS ADHD access, see our article on Right to Choose ADHD changes.
The case of Coventry and Warwickshire NHS board, which paused ADHD referrals for adults over 25, leaving thousands of people with no NHS assessment pathway, illustrates the consequences directly. Reports from that period cited individuals paying up to £1,500 privately for assessments they had no other means of accessing. This is not a market failure driven by patient impulsivity. It is the predictable consequence of a system that cannot meet clinical need.
In this environment, turning to private care is not a lifestyle choice. For most of the people doing it, it is a clinical necessity. And offering ethical payment options to make that care accessible is not exploitation. It is what responsible private provision looks like when public services have failed to keep pace with demand.
Private care is also not without its own legitimate quality concerns. Not all private ADHD providers operate to the same clinical standard, and patients deserve guidance on how to identify reputable, clinically rigorous services. For more on this, see our article on private ADHD clinics and red flags to watch for.
The suggestion, sometimes implicit in the media coverage being discussed, that seeking an ADHD assessment and paying for it via Klarna represents a financially risky or potentially harmful course of action, needs to be set alongside the equally important question of what the financial, health, and social consequences of not seeking assessment look like.
Research on this question is unambiguous. Biederman and colleagues demonstrated improved occupational and functional outcomes following ADHD treatment. Dalsgaard and colleagues showed reduced adverse life outcomes with appropriate ADHD care. Research published in the New England Journal of Medicine by Lichtenstein and colleagues found that ADHD medication was associated with reduced negative outcomes including those linked to socioeconomic instability.
The financial risk of untreated ADHD is substantially and consistently greater than the financial risk of paying for assessment. For an adult who has spent years or decades paying the ADHD tax across their career, relationships, and health, accessing a timely assessment is an investment in functional outcomes, not a reckless expenditure.
Delaying diagnosis is not a financially prudent or clinically neutral position. It is a position with measurable costs that fall primarily on the individual.
It is worth being clear about what distinguishes responsible private ADHD provision from the practices that legitimately warrant scrutiny.
Reputable private ADHD providers conduct comprehensive assessments that adhere to NICE guidelines and established diagnostic frameworks. They employ qualified clinicians with relevant specialist training. They maintain clear and transparent information about costs and payment options. They provide appropriate ongoing care including medication titration and follow-up, rather than diagnosis-only services. And they operate under appropriate regulatory oversight.
These providers are not the same as the clinic models that have attracted justified criticism for inadequate assessments, rushed prescribing, and poor clinical governance. Conflating the two, or treating all private ADHD provision as equivalent in quality or intent, is inaccurate and unhelpful.
Scrutiny of the private ADHD market is appropriate and necessary. That scrutiny should be directed at clinical quality, regulatory compliance, and transparency, not at the payment mechanisms used to make care financially accessible to people with limited means and limited NHS access. For more on what to look for when choosing private ADHD assessment, see our article on private ADHD clinics and what to look for.
There is a clear pattern in coverage that generates concern: ADHD is discussed without adequate input from trained clinicians, complex neuropsychological data is interpreted by commentators without relevant expertise, and the condition is framed through a moral or behavioural lens that the evidence does not support.
Responsible reporting on ADHD requires consultation with trained clinicians who understand neurodevelopmental conditions. It requires engagement with the peer-reviewed research rather than reliance on anecdote. It requires careful use of language that does not reinforce stigma around neurodivergent financial behaviour. And it requires acknowledging the systemic failures in NHS access that have created the conditions in which the private market discussion is even relevant.
ADHD is a medical condition. Public discourse about the people seeking assessment for it deserves the same clinical rigour that would be expected in discussion of any other medical condition.
The framing of payment plans for ADHD assessments as inherently problematic reflects a failure to understand ADHD as a neurodevelopmental condition with well-evidenced impacts on financial functioning. Clinicians who work with adults with ADHD consistently see the real cost of delayed diagnosis: in careers derailed, relationships damaged, mental health deteriorated, and financial situations worsened by years of unmanaged executive dysfunction.
Reducing barriers to assessment, including through financial accessibility measures, is not a concession to impulsive behaviour. It is an application of the same accessibility principles that underpin good disability-inclusive care. The people seeking these assessments are not naive consumers. They are individuals who have, in many cases, already paid an enormous personal price for a condition that went unidentified.
For healthcare professionals who want to develop their clinical expertise in ADHD assessment and management, including the ability to engage with public discourse from an evidence-based foundation, our ADHD assessor training course and ADHD training for professionals provide CPD-certified education grounded in current international evidence.
If you are considering private ADHD assessment and are concerned about cost, payment plans offered by regulated providers are a legitimate option. The key is to ensure you understand the terms fully before committing, and to choose a provider whose clinical standards are transparent and robust.
If you are comparing providers, ask specifically about the qualifications of the clinician who will conduct your assessment, the format and length of the assessment, whether NICE guidelines are followed, what happens after diagnosis including medication and follow-up support, and what the full cost will be including any ongoing care.
If you are unsure about a provider's credibility, checking that they are registered with the Care Quality Commission (CQC) in England or equivalent regulatory body in your country, and that the assessing clinician is registered with the relevant professional body such as the GMC or NMC, is a baseline check that any reputable provider should pass.
If you are on an NHS waiting list, it is worth asking your GP about the Right to Choose pathway and whether it is still available in your area. Changes to this pathway have made it less accessible in some regions, but it remains an option in others. For current information on access pathways, see our article on Right to Choose ADHD changes.
Is it financially irresponsible to use Klarna for an ADHD assessment?
The evidence does not support this framing. For many people with ADHD, structured instalment payments are more cognitively manageable and financially predictable than a single large upfront payment. Using a payment plan transparently and intentionally to access care that would otherwise be inaccessible is a financially considered decision, not an impulsive one.
Are private ADHD clinics that offer payment plans exploitative?
Not inherently. Offering transparent, ethical payment options to make care financially accessible is a reasonable practice. Exploitation would involve misleading patients about costs, providing substandard assessments, or failing to support patients appropriately after diagnosis. These are quality and transparency concerns, not payment mechanism concerns.
Why can't people just wait for NHS assessment?
In many areas, NHS waiting times for adult ADHD assessment are five to ten years or longer. For most adults experiencing significant functional impairment, this is not a clinically acceptable wait. The option to access timely private care, even at personal cost, reflects a rational response to a system that cannot currently meet demand.
Does getting an ADHD diagnosis actually improve financial outcomes?
Research consistently shows that appropriate ADHD diagnosis and treatment are associated with improved occupational functioning, reduced adverse life outcomes, and better long-term stability. The financial case for assessment is supported by evidence. The financial risk of continued undiagnosed ADHD is substantially greater than the cost of assessment.
How do I know if a private ADHD provider is reputable?
Key indicators include CQC registration, qualified and registered clinicians, comprehensive assessment processes aligned with NICE guidelines, transparent pricing, and clear provision for ongoing care after diagnosis. Providers who offer very rapid assessments, prescribe immediately without adequate clinical review, or lack regulatory registration warrant caution.
The framing of payment plans for ADHD assessments as exploitative or financially reckless reflects a gap in clinical understanding that public discourse on neurodevelopmental conditions cannot afford.
ADHD has measurable, well-documented effects on financial functioning. The people seeking assessment are not impulsive consumers. They are individuals navigating a healthcare system with NHS waiting lists measured in years, carrying the accumulated cost of unmanaged ADHD, and trying to access the support they need through whatever means are available.
Payment plans reduce a barrier to care. They do not create one.
When media coverage on this topic engages fully with the neurodevelopmental research, the NHS access crisis, and the clinical evidence on what untreated ADHD costs individuals and society, the picture it produces will look very different from the one currently in circulation.
Until then, clinicians, patient advocates, and informed commentators have a responsibility to provide the context that the coverage is missing.
Medical Disclaimer
This article presents a clinically informed perspective drawing on peer-reviewed research. It does not constitute financial or legal advice. References to specific research studies are provided for educational purposes.
